STOCK TITAN

PAVmed Inc. - PAVM STOCK NEWS

Welcome to our dedicated page for PAVmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on PAVmed stock.

PAVmed Inc. (Nasdaq: PAVM) is a cutting-edge medical device company focused on bringing innovative medical technologies from concept to commercialization with exceptional speed and efficiency. Headquartered in New York, PAVmed is led by three seasoned medical device entrepreneurs. The company is structured to develop and commercialize a diversified pipeline of breakthrough products that address unmet clinical needs, thereby enhancing and accelerating value creation through a business model centered on capital and time efficiency.

PAVmed operates in a single segment as a medical technology company, with three primary lines of business: Diagnostics, Medical Devices, and Digital Health. Through its majority-owned subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), the company offers products such as the EsoGuard Esophageal DNA Test and the EsoCheck Esophageal Cell Collection Device. These tools are designed for the early detection of esophageal precancer, aiming to prevent esophageal cancer by identifying at-risk patients early.

Another significant subsidiary is Veris Health Inc., which focuses on enhanced personalized cancer care through remote patient monitoring. Veris is developing an innovative implantable physiological monitor that interfaces with the Veris Cancer Care Platform, providing real-time health data to improve patient outcomes.

Recent notable achievements include a partnership between Lucid Diagnostics and the Esophageal Cancer Action Network (ECAN) to promote Esophageal Cancer Awareness Month, highlighting the critical link between chronic heartburn and esophageal cancer. Additionally, Lucid has published positive data from a National Cancer Institute-sponsored clinical validation study, which demonstrated EsoGuard's unprecedented early detection capabilities for esophageal precancer compared to traditional endoscopic methods.

PAVmed's commitment to innovation is further exemplified by its business updates and financial results discussions, providing shareholders and potential investors with transparent insights into the company's operational progress and strategic direction. The company's diversified approach in the medical technology sector positions it as a significant player in advancing healthcare and improving patient outcomes.

Rhea-AI Summary

Lucid Diagnostics, a cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., will hold a business update conference call and webcast on May 13, 2024, at 8:30 AM ET. The call will feature Lucid's CEO providing an operational overview and growth strategy, along with the CFO discussing first-quarter 2024 financial results. Investors can access the webcast on the company's website or join via telephone.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
none
-
Rhea-AI Summary

Lucid Diagnostics Inc. (Nasdaq: LUCD) announced the publication of positive data from a National Cancer Institute-sponsored study on EsoGuard® Esophageal Precancer Testing, showing 89% sensitivity in detecting early precancer. The study strengthens EsoGuard's clinical data and supports efforts for commercial and Medicare coverage.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
none
-
Rhea-AI Summary

PAVmed Inc. (Nasdaq: PAVM) announced a collaboration between its subsidiary, Veris Health Inc., and The Ohio State University Comprehensive Cancer Center to implement a pilot program using the Veris Cancer Care Platform. This platform aims to enhance personalized cancer care through digital health tools and remote monitoring, offering improved patient outcomes and satisfaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.96%
Tags
none
Rhea-AI Summary

Lucid Diagnostics, a cancer prevention medical diagnostics company, partners with the Esophageal Cancer Action Network (ECAN) to raise awareness during Esophageal Cancer Awareness Month. The partnership aims to educate about the link between heartburn and esophageal cancer, promoting early detection for prevention. Public service videos are being displayed in Times Square, emphasizing the importance of screening for those at risk.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
partnership
-
Rhea-AI Summary
Lucid Diagnostics Inc. (LUCD) announced that their President & COO will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference. The webcast will be available on their website, with a replay option for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
conferences
-
Rhea-AI Summary
PAVmed Inc. reports a 33% sequential increase in quarterly revenue and launches PMX incubator for technology development. Lucid Diagnostics Inc. shows revenue growth and expansion in clinical data evidence. Veris Health Inc. focuses on financing from academic and regional cancer centers. Financially, the company had a net loss but positive revenue growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.52%
Tags
Rhea-AI Summary
Lucid Diagnostics Inc. (LUCD) reports a 33% sequential increase in Quarterly EsoGuard® revenue. The company is focused on expanding clinical validity and utility data to drive medical policy coverage, including potential Medicare coverage. Lucid's recent business update highlights revenue growth, stable test volume, improving revenue cycle management, and progress in engaging with major commercial payors for positive coverage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.79%
Tags
-
Rhea-AI Summary
Lucid Diagnostics Inc. announces promising results from a VA screening study showing EsoGuard sensitivity of 92.9% and negative predictive value of 98.6% for esophageal precancer detection. The study highlights EsoGuard as a powerful screening tool for early detection of esophageal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
none
-
Rhea-AI Summary
PAVmed Inc. announces the launch of PMX incubator, in a joint venture with Hatch Medical, to advance PortIO Implantable Intraosseous Vascular Access Device and other technologies. The partnership aims to facilitate capital formation for development and commercialization, starting with PortIO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
none
Rhea-AI Summary
Lucid Diagnostics Inc. (LUCD) and collaborators will present data on three studies on EsoGuard® esophageal precancer testing and one on a new genetic classifier of esophageal neoplasia at the Digestive Disease Week (DDW) Annual Meeting 2024. The studies aim to expand the clinical evidence base for EsoGuard testing to detect esophageal precancer and introduce a new genetic classifier.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.8%
Tags
none

FAQ

What is the current stock price of PAVmed (PAVM)?

The current stock price of PAVmed (PAVM) is $0.6561 as of December 24, 2024.

What is the market cap of PAVmed (PAVM)?

The market cap of PAVmed (PAVM) is approximately 7.3M.

What does PAVmed Inc. do?

PAVmed Inc. is a medical technology company that develops and commercializes innovative medical devices, diagnostics, and digital health solutions.

What are PAVmed's main products?

PAVmed's main products include the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device, designed for early detection of esophageal precancer.

What is EsoGuard?

EsoGuard is a DNA test performed on esophageal cells collected noninvasively with EsoCheck, used for early detection of esophageal precancer.

Who leads PAVmed Inc.?

PAVmed Inc. is led by three experienced medical device entrepreneurs focused on rapid commercialization of medical technologies.

What recent achievements has PAVmed made?

Recent achievements include a partnership with ECAN for Esophageal Cancer Awareness Month and a successful clinical validation study for EsoGuard.

What is Veris Health?

Veris Health, a subsidiary of PAVmed, focuses on personalized cancer care through remote patient monitoring and is developing an implantable physiological monitor.

How does PAVmed enhance value creation?

PAVmed enhances value creation by employing a business model focused on capital and time efficiency, quickly bringing innovative products to market.

What areas does PAVmed operate in?

PAVmed operates in diagnostics, medical devices, and digital health sectors within the medical technology industry.

How can I access PAVmed's latest updates?

You can access the latest updates on PAVmed's operations and financial performance through their business update conference calls and webcasts.

Where can I find more information about PAVmed?

For more information, please visit PAVmed's official website at www.pavmed.com.

PAVmed Inc.

Nasdaq:PAVM

PAVM Rankings

PAVM Stock Data

7.26M
9.73M
10.39%
14.6%
2.82%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
NEW YORK